Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Sep 20;39(9):BSR20190691.
doi: 10.1042/BSR20190691. Print 2019 Sep 30.

Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis

Haiqin Peng  1 , Zhanzhan Li  1 , Yujiao Long  1 , Jiahui Li  1 , Zhiyuan Liu  1 , Rongrong Zhou  2
Affiliations
Meta-Analysis

Clinical value of a plasma Epstein-Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis

Haiqin Peng et al. Biosci Rep. .

Abstract

Background: To evaluate the diagnostic value of Epstein-Barr virus (EBV) DNA in nasopharyngeal carcinoma (NPC) patients with locoregional or distant recurrence.

Methods: Articles related to the diagnosis of recurrent or metastatic NPC by the detection of EBV DNA in plasma or serum were retrieved from different databases. Sensitivity, specificity, summary receiver operating characteristic (SROC) curves, and likelihood ratios were pooled to assess the diagnostic value of individual diagnostic tests.

Results: This meta-analysis pooled 25 eligible studies including 2496 patients with NPC. The sensitivity, specificity, positive likelihood ratio (+LR), and negative likelihood ratio (-LR) of EBV DNA in the diagnosis of NPC were 0.858 (95% confidence interval (CI): 0.801-0.901), 0.890 (95% CI: 0.866-0.909), 7.782 (95% CI: 6.423-9.429) and 0.159 (95% CI: 0.112-0.226), respectively. The diagnostic odds ratio (DOR) was 48.865 (95% CI: 31.903-74.845). The SROC for EBV DNA detection was 0.93 (95% CI: 0.90-0.95).

Conclusion: The detection of EBV DNA for the diagnosis of recurrent or metastatic NPC has good sensitivity and specificity and might be helpful in monitoring recurrent or metastatic NPC.

Keywords: Epstein-Barr Virus DNA; Meta-Analysis; metastatic; nasopharyngeal carcinoma; recurrent.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. Flow chart of the selection process for eligible studies
Figure 2
Figure 2. Forest plots of pooled sensitivity for EBV DNA assay in the recurrence or/and metastasis of NPC
Figure 3
Figure 3. Forest plots of pooled specificity for EBV DNA assay in the recurrence or/and metastasis of NPC
Figure 4
Figure 4. Forest plots of pooled DOR for EBV DNA assay in the recurrence or/and metastasis of NPC
Figure 5
Figure 5. Summary ROC curve of all included articles with 95% CIs for pooled sensitivity and pooled specificity and the 95% prediction interval
Figure 6
Figure 6. Risk of bias and applicability concerns graph
Figure 7
Figure 7. Risk of bias and applicability concerns summary
Figure 8
Figure 8. Funnel plot with pseudo 95% confidence limits for EBV DNA assay in the recurrence or/and metastasis of NPC
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marks J.E., Phillips J.L. and Menck H.R. (1998) The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 83, 582–588 - PubMed
    1. Wei W.I. and Sham J.S. (2005) Nasopharyngeal carcinoma. Lancet 365, 2041–2054 10.1016/S0140-6736(05)66698-6 - DOI - PubMed
    1. Parkin D.M., Bray F., Ferlay J. and Pisani P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 10.3322/canjclin.55.2.74 - DOI - PubMed
    1. Jiang G.M., Wang H.S., Du J., Ma W.F., Wang H., Qiu Y.. et al. (2017) Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation. Cancer Immunol. Res. 5, 42–51 10.1158/2326-6066.CIR-16-0102 - DOI - PubMed
    1. Tan W.L., Tan E.H., Lim D.W., Ng Q.S., Tan D.S., Jain A.. et al. (2016) Advances in systemic treatment for nasopharyngeal carcinoma. Chin. Clin. Oncol. 5, 21 10.21037/cco.2016.03.03 - DOI - PubMed

Publication types

MeSH terms